First-in-Human, Phase 1 Study of BGB-26808 (Hematopoietic Progenitor Kinase 1 Inhibitor) ± Tislelizumab in Advanced Solid Tumors

First-in-Human, Phase 1 Study of BGB-26808 (Hematopoietic Progenitor Kinase 1 Inhibitor) ± Tislelizumab in Advanced Solid Tumors

Poster Number: 1564P, ESMO 2025

Dokument

20 Nov. 2025

A First-in-Human, Phase 1 Study of BGB-15025 (Hematopoietic Progenitor Kinase 1 [HPK1] inhibitor) as Monotherapy and in Combination With Tislelizumab (anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Dokument

19 Nov. 2025

Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial

Trotman et al. 2024. https://doi.org/10.1080/03007995.2024.2409837.

Dokument

12 Aug. 2025

COMPARISON OF TREATMENT-EMERGENT ADVERSE EVENTS OF ACALABRUTINIB AND ZANUBRUTINIB IN CLINICAL TRIALS IN B-CELL MALIGNANCIES: A SYSTEMATIC REVIEW AND META-ANALYSIS

Poster 632 from Hwang et al. EHA 2023.

Dokument

11 Aug. 2025

Squamous cell carcinoma of the oesophagus: Tislelizumab, improved survival – Interview with Alexander Siebenhüner

Adeline Beijns, Helvete, October 2024

Dokument

24 Juli 2025